Overview

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Sitagliptin Phosphate